VRDN Q1 2019 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$2B

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$372,000-92.2% YoY

Gross Profit

-$8M-2252.4% margin

Operating Income

-$12M-3154.8% margin

Net Income

-$12M-3126.1% margin

EPS (Diluted)

$-5.65

QoQ Revenue Growth

-21.8%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$55M

Total Liabilities

$14M

Stockholders' Equity

$41M

Cash & Equivalents

$18M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$372,000	$5M	-92.2%
Gross Profit	-$8M	-$2M	-414.4%
Operating Income	-$12M	-$5M	-154.1%
Net Income	-$12M	-$5M	-149.5%